Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort - Wikidata - wikimedia - TriplyDB

Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort

Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort

http://www.wikidata.org/entity/Q33795567

about

Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications My treatment approach to rheumatoid arthritis Effectiveness of tumor necrosis factor α blockers in early axial spondyloarthritis: data from the DESIR cohort.Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data.Future therapeutic targets in rheumatoid arthritis?A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats.Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry.We should not forget the foot: relations between signs and symptoms, damage, and function in rheumatoid arthritis DAS steered therapy in clinical practice; cross-sectional results from the METEOR database A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study.Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis.Rheumatoid arthritis--early diagnosis and disease management Predictors of change in bodily pain in early rheumatoid arthritis: an inception cohort study GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate.Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis.Pain in rheumatoid arthritis.PROMs in inflammatory arthritis: moving from static to dynamic.Rheumatoid arthritis in the elderly in the era of tight control.Dose optimization of infliximab in patients with rheumatoid arthritis.Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update.The optimal combination therapy for the treatment of early rheumatoid arthritis.Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?Guidelines for the drug treatment of rheumatoid arthritis.Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry.Treat to Target in Inflammatory Bowel Disease.[Systematic literature research for S1 guidelines on sequential medical treatment of rheumatoid arthritis].Novel Concepts in Psoriatic Arthritis Management: Can We Treat to Target?

P2860

Q26738960-8D5580CB-A6ED-4DAB-B56A-59840036A82F Q26829955-DB6A6308-F1ED-428E-ACCE-2E1563A22323 Q30776497-FFD5D01D-8E26-4D4B-844B-4EA790693F63 Q30984829-46EB1139-E0D0-4B33-B098-3D364C81B96B Q33841419-9CBF1A43-E549-4AC9-B6B1-3D5E930A8874 Q34552239-A062D2C8-2D1D-4B4C-8639-C3629D8A7BAD Q35065233-2C3B9914-6C1D-48B8-B3D8-A68C1229037A Q35463979-713BD4BA-7C5F-44F5-B898-B9EB2B28D6D5 Q35895890-EB86CB7C-4A9F-4A9B-9B94-D9E5FB6476FC Q35907768-4A55313E-DD6D-460B-935A-4F4C59F95D5E Q36164886-D30ADBF7-432D-49B3-8169-BC6FE6179E81 Q36907694-33EF6163-9C65-45CC-8D44-12139536F0A4 Q37023870-DD4F0B0D-7347-43D4-A479-33E3130968AF Q37043713-3D38C4AF-5C3C-408A-ADD5-7435AD195A7F Q37165244-FE8CE7DC-36FE-4CB7-8A38-AAC3C266FD32 Q37177583-B7E36260-20F3-458D-9CF6-2DA1B2C4CCCA Q37703462-313BBC89-F7BA-443F-91BF-4B5AA10ECB05 Q38056432-491098F0-26B7-49FD-A4E9-7C60A3669CE5 Q38097709-84EE165E-360C-43CE-B095-4E86EE1ECEB8 Q38150731-296CA2D3-8216-4BD3-BE2C-5A1E24678B1A Q38182728-05270B68-E024-4468-A142-5EE4464F8C0F Q38476881-C5F41C34-03DA-4999-A85E-6DE32BDA2EE5 Q38492012-8649E605-E4A2-4550-B62C-F07D3AAAEF5C Q38522457-4A043A01-8E15-499F-8DFE-AC547429570E Q40847456-C987524A-74CD-4514-8A26-612AAEF9D4F5 Q43675571-C18129A4-AA89-42A6-B9FD-C2373B14FE1C Q48278236-381A8B5D-FA71-41B6-808B-B4A35ADBEF6F Q50881664-44CAB7EE-55F3-4BD3-9BB8-9F4B311E9D06 Q52887079-BE4B7C2C-F0B9-4556-8AAD-F7B222579DA3 Q58724084-0E7FD72A-DCC2-450B-BB1A-4E6B5AF2606B

P2860

Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort

http://www.wikidata.org/entity/Q33795567

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Disease activity score-driven ...... UEPARD trial and ESPOIR cohort

@ast

Disease activity score-driven ...... UEPARD trial and ESPOIR cohort

@en

type

label

Disease activity score-driven ...... UEPARD trial and ESPOIR cohort

@ast

Disease activity score-driven ...... UEPARD trial and ESPOIR cohort

@en

prefLabel

Disease activity score-driven ...... UEPARD trial and ESPOIR cohort

@ast

Disease activity score-driven ...... UEPARD trial and ESPOIR cohort

@en

P1433

Q33795567-E94CE357-C4C0-4987-9943-D5F39AEC8A44

P1476

Q33795567-F291136D-5080-445B-B100-A6618C7D1A90

P2093

Q33795567-2A6AEE7A-86C6-4D34-844D-7C2FC53100C1

Q33795567-406EF361-7E01-40BD-A5A3-DED524C36999

Q33795567-4DD93C4F-7DC1-497B-B378-F79BADE80685

Q33795567-6D7C468F-C3D3-44BE-A44B-5881CC5904CD

Q33795567-9CA73D25-2586-4592-A095-AD842841B53E

Q33795567-B93682EE-D51C-4610-8463-C700BB228048

Q33795567-F8DB716A-1086-436D-8661-6D521F0D2A3D

Q33795567-FB221F6F-E1AB-48D4-9C20-79843BA28A8A

P2860

Q33795567-09E92C71-2A2E-4829-85AE-819C58EF0846

Q33795567-1F3AC9BB-1F5A-4627-AC33-6672CC851D5B

Q33795567-22A88E8B-E5DD-4720-A9AD-DD0D4229DB0A

Q33795567-416CFF37-FE3B-4BBC-8393-9E691B54594D

Q33795567-4FA11CDD-0C9C-45EB-B878-884352BFA8BB

Q33795567-507443F8-6D1F-497C-AD55-C658CF6A8535

Q33795567-A50AE974-4E41-4885-A629-9756D0E5B6CA

Q33795567-E34015A4-ADDA-4C1D-9AEA-D2278A818645

Q33795567-F703D70A-2EF8-417C-87EB-68A9B80216AB

P304

Q33795567-C2BB5343-D5DD-4BB7-9D1F-9EE5AB0C66F9

P31

Q33795567-F20D2E03-1510-4796-8D0C-AFEBB158B57A

P356

Q33795567-DE4CA66E-961A-4816-A147-08FF58058C58

P407

Q33795567-1EDD8A5E-465D-4CCA-BE1F-4EF930B66EDE

P433

Q33795567-22B10503-3FA7-4C02-A04B-0E6BAA8D2373

P478

Q33795567-1CBF1F72-EFDE-4FA8-85D8-E2C414CC2DAA

P577

Q33795567-BF2FD0CA-3BE8-4FC7-82E5-C699B7C5626D

P5875

Q33795567-42572F3E-AA77-47A1-B19F-628F6B503280

P698

Q33795567-25C60AD8-B9DD-4C0C-917C-F057C3D1A570

P932

Q33795567-5B22D2F7-B373-4BDF-BD8E-791E44FD187A

P356

ARD.2010.137695

P1433

Annals of the Rheumatic Diseases

P1476

Disease activity score-driven ...... UEPARD trial and ESPOIR cohort

@en

P2093

B Fautrel

http://www.w3.org/2001/XMLSchema#string

C Lukas

http://www.w3.org/2001/XMLSchema#string

F Roux

http://www.w3.org/2001/XMLSchema#string

J Sibilia

http://www.w3.org/2001/XMLSchema#string

L Gossec

http://www.w3.org/2001/XMLSchema#string

M Dougados

http://www.w3.org/2001/XMLSchema#string

M Soubrier

http://www.w3.org/2001/XMLSchema#string

S Patternotte

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

The Hawthorne effect, sponsored trials, and the overestimation of treatment effectiveness.

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients.

Factors determining a DMARD initiation in early inflammatory arthritis patients. The ESPOIR cohort study

P304

611-615

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2010.137695

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49762392

http://www.w3.org/2001/XMLSchema#string

P698

21242235

http://www.w3.org/2001/XMLSchema#string

P932

3048626

http://www.w3.org/2001/XMLSchema#string